Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy – Authors' reply Correspondence

  

Authors:	André, T.; Diaz, L. A. Jr; Shiu, K. K.
Title:	Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy – Authors' reply
Keywords:	cancer chemotherapy; survival rate; drug efficacy; letter; progression free survival; carcinoma, non-small-cell lung; lung neoplasms; colorectal carcinoma; lung tumor; cytotoxic t lymphocyte antigen 4; trend study; programmed death 1 receptor; non small cell lung cancer; humans; human; pembrolizumab; immune checkpoint inhibitors
Journal Title:	Lancet Oncology
Volume:	23
Issue:	6
ISSN:	1470-2045
Publisher:	Elsevier Science, Inc.
Date Published:	2022-06-01
Start Page:	e246
Language:	English
DOI:	10.1016/s1470-2045(22)00299-6
PUBMED:	35654063
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85131119100&doi=10.1016%2fS1470-2045%2822%2900299-6&partnerID=40&md5=9984004cfb79eb216047d31de8f6d3a8
Notes:	Letter -- Export Date: 1 July 2022 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/195521